https://www.selleckchem.com/pr....oducts/elamipretide-
Neurological outcomes of the remaining 14 infants in NT group were as follows normal 21.4 %, mild impairments 14.3 %, and severe impairments 64.3 %. The proportion of infants with severe impairments in FT group was significantly lower than that in NT group (18.2 % vs 64.3 %, p less then 0.05). This is the first trial demonstrating that the combination of Ig FT and NT with antiviral drugs may be more effective in improving neurological outcomes of newborns with symptomatic cCMV as compared to NT only.The main aim of the stud
Mi piace
Commento
Condividi
